Cannabidiol (CBD) potentiates physiological and behavioral markers of hypothalamic-pituitary-adrenal (HPA) axis responsivity in female and male mice
Preprint
Abstract
Rationale: Clinical literature indicates there may be a therapeutic use of cannabidiol (CBD) for stress-related disorders. Preclinical literature remains conflicted regarding the underlying neurobehavioral mechanisms, reporting mixed effects of CBD (increased, decreased, or no effect) on anxiety- and fear-related behaviors. Preclinical data demonstrated that CBD modulates hypothalamus-pituitary-adrenal (HPA) axis gene expression; it is unknown whether CBD changes HPA axis responsivity and how this relates to altered behavior. Objectives: We aimed to evaluate whether acute or chronic CBD administration would alter physiological and behavioral measures of HPA axis responsivity in male or female mice. Methods: C57BL/6 mice of both sexes were injected with vehicle or CBD (30 mg/kg, i.p.) daily for 26 days. Plasma corticosterone (CORT) levels were evaluated following dexamethasone suppression and adrenocorticotropin hormone stimulation tests after acute and chronic CBD exposure. After chronic CBD, mice were tested for anxiety-like behavior using an elevated plus maze (EPM) and associative fear learning and memory using a trace fear conditioning (FC) protocol. Results: Compared to vehicle, CBD induced a state of HPA axis hyperactivation, an effect which was significant in males; it also normalized anxiety-like behavior in female mice classified as having HPA axis hypofunction and primed all female mice for enhanced conditioned responding. Significant sex differences were also detected: females had greater plasma CORT levels and HPA axis responsivity than males, exhibited less EPM anxiety-like behavior, and were more responsive during FC. Conclusions: CBD potentiated physiological and behavioral markers of HPA axis function and normalized anxiety-like behavior in a sex-specific manner. This observation has implications for cannabinoid-based drug development targeting individuals with stress-related disorders involving HPA axis hypofunction pathology.Keywords
All Related Versions
- Published version: Psychopharmacology, 243 (2), 287.
This publication has 65 references indexed in Scilit:
- Cannabidiol tempers alcohol intake and neuroendocrine and behavioural correlates in alcohol binge drinking adolescent rats. Focus on calcitonin gene‐related peptide's brain levelsPhytotherapy Research, 2023
- Cannabinoid Regulation of Fear and Anxiety: an UpdateCurrent Psychiatry Reports, 2019
- Regulation of the Hypothalamic‐Pituitary‐Adrenocortical Stress Response2016
- Cannabidiol as a Potential Treatment for Anxiety DisordersNeurotherapeutics, 2015
- Adjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of Chronic Military Service–Related PTSDJAMA, 2011
- Childhood Adversities and Adult Psychiatric Disorders in the National Comorbidity Survey Replication IArchives of General Psychiatry, 2010
- Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005
- Feast and Famine: Critical Role of Glucocorticoids with Insulin in Daily Energy FlowFrontiers in Neuroendocrinology, 1993
- Cannabinoid interactions with glucocorticoid receptors in rat hippocampusBrain Research, 1990
- Antianxiety effect of cannabidiol in the elevated plus-mazePsychopharmacology, 1990